Regulatory
RFK Jr. Reclassification
2026 HHS policy move reclassifying 14 peptides, expanding legal compounding access.
Definition
In 2026, HHS under RFK Jr. moved 14 peptides off Category 2 and onto the FDA bulk substance eligibility list, restoring legal compounding access. This is a significant regulatory shift for the peptide industry.
Related terms
Back to the full peptide glossary.